Investment Thesis
Henry Schein demonstrates resilient top-line growth in a defensive healthcare distribution sector, with net income growth outpacing revenue expansion. However, severely negative operating cash flow (-$97M) despite positive earnings signals acute working capital stress and potential quality-of-earnings concerns, while razor-thin net margins (3.2%) and abysmal returns (ROE 3.3%, ROA 0.9%) indicate structural profitability challenges.
Strengths
- Revenue and net income growth (+4.0% and +5.3% YoY) in defensive healthcare supplies sector resistant to economic cycles
- Manageable leverage (Debt/Equity 0.71x) with adequate interest coverage (4.7x) to service obligations
- Operational scale ($3.4B revenue, $11.3B assets) provides competitive moat in distribution
Risks
- Negative operating cash flow (-$97M) and free cash flow (-$122M) indicate severe working capital deterioration despite positive earnings; unsustainable without external financing
- Critically thin net margin (3.2%) and anemic returns (ROE 3.3%, ROA 0.9%) limit pricing power and operational flexibility in competitive distribution market
- Quick ratio of 0.75x with only $138M cash against $2.3B debt and operational burn suggests emerging liquidity stress
Key Metrics to Watch
- Operating cash flow trajectory and working capital components (inventory, receivables) - must return to positive to confirm earnings quality
- Gross margin stability - deterioration would be existential given thin operating margins
- Debt covenant compliance and access to credit facilities - critical for financing ongoing negative FCF
Financial Metrics
Revenue
3.4B
Net Income
107.0M
EPS (Diluted)
$0.92
Free Cash Flow
-122.0M
Total Assets
11.3B
Cash
138.0M
Profitability Ratios
Gross Margin
31.8%
Operating Margin
5.4%
Net Margin
3.2%
ROE
3.3%
ROA
0.9%
FCF Margin
-3.6%
Balance Sheet & Liquidity
Current Ratio
1.36x
Quick Ratio
0.75x
Debt/Equity
0.71x
Debt/Assets
57.3%
Interest Coverage
4.67x
Long-term Debt
2.3B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:26:52.429149 |
Data as of: 2026-03-28 |
Powered by Claude AI